Investing.com --Bausch + Lomb Corp (NYSE:BLCO) shares tumbled more than 12% on Wednesday in New York Stock Exchange after report that Blackstone (NYSE:BX) could back away from a joint bid to acquire the eyecare company, raising doubts about one of the largest healthcare buyouts of the year.
The private equity giant had teamed up with investor TPG in October to explore a bid for Bausch + Lomb . However, Financial Times reported citing sources that Blackstone has grown wary of the seller’s high price expectations.
Citi downgraded Bausch + Lomb to “neutral” from “buy” in a note on Wednesday, slashing its price target to $22 from $24.
The auction process for Bausch + Lomb, known for its contact lenses, dry eye treatments, and surgical ophthalmology devices, began earlier this year as its debt-laden parent, Bausch Health, seeks to reduce its liabilities.
Related Articles
Bausch + Lomb down after report that Blackstone could back away from takeover bid
Albertsons demands billions from rival Kroger after terminating merger bid
Global shares, US dollar rise as inflation data reinforces Fed hopes
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.